ArticleThe oncologist2020

Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).

Lola-Jade Palmieri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.